New strategies in ovarian cancer: Translating the molecular complexity of ovarian cancer into treatment advances

Clinical Cancer Research

Volumn 20, Issue 20, 2014, Pages 5150-5156

  Liu, Joyce ^a   Matulonis, Ursula A ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CYCLIN E; CYCLIN E1; FARLETUZUMAB; FOCAL ADHESION KINASE INHIBITOR; FOLATE RECEPTOR; IPILIMUMAB; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NIRAPARIB; NIVOLUMAB; OLAPARIB; RUCAPARIB; TALAZOPARIB; VELIPARIB; VINTAFOLIDE; ANTINEOPLASTIC AGENT;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; GENOMICS; HUMAN; MOLECULAR PATHOLOGY; OVARY CANCER; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); ANIMAL; FEMALE; MOLECULARLY TARGETED THERAPY; MULTIMODALITY CANCER THERAPY; OVARIAN NEOPLASMS; TRANSLATIONAL RESEARCH;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; FEMALE; GENOMICS; HUMANS; MOLECULAR TARGETED THERAPY; OVARIAN NEOPLASMS; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84908665045     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-1312     Document Type: Review

References (75)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics 2014. CA Cancer J Clin 2014;64:9-29.
3. Buys SS, Partridge E, Black A, Johnson CC, Lamerato L, Issacs C, et al. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Randomized Controlled trial. JAMA 2011;305:2295-303.
4. Jayson GC, Kohn EC, Kitchener HC, Ledermann JA. Ovarian cancer. Lancet 2014 Apr 17. [Epub ahead of print].
5. Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, et al., editors. SEER cancer statistics review, 1975-2011, National Cancer Institute [Internet]. Bethesda, MD: National Cancer Institute; 2014 [cited 2014 Jul 10]. Available from: http://seer.cancer.gov/csr/1975-2011/.
6. National Comprehensive Cancer Network. NCCN guidelines for treatment of cancer by site: ovarian cancer [Internet]. Fort Washington, PA: The Network; 2009 [cited 2014 Jul 10]. Available from: http://www.nccn.org.
7. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334:1-6.
8. Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006;354:34-43.
9. Katsumata N, Yasuda M, Isonishi S, Takahashi F, Michimae H, Kimura E, et al. Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial. Lancet Oncol 2013;14:1020-6.
10. Vergote I, Tropé CG, Amant F, Kristensen GB, Ehlen T, Johnson N, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 2010;363:943-53.
11. Bookman MA, Gilks CB, Kohn EC, Kaplan KO, Huntsman D, Aghajanian C, et al. Better therapeutic trials in ovarian cancer. J Natl Cancer Inst 2014;106;dju029.
12. Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011;365:2473-83.
13. Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011;365:2484-96.
14. Aghajanian C, Blank SV, Goff BA, Judson PL, Teneriello MG, Husain A, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 2012;30:2039-45.
15. Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J Clin Oncol 2014;32:1302-8.
16. Monk BJ, Poveda A, Vergote I, Raspagliesi F, Fujiwara K, Bae DS, et al. Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial. Lancet Oncol 2014;15:799-808.
17. Ledermann J, Perren TJ, Raja FA, Embleton A, Rustin G, Jayson GC, et al.Randomised double-blind phase III trial of cediranib (AZD 2171) in relapsed platinum sensitive ovarian cancer: results of the ICON6 trial [abstract]. In: Proceedings of the 13th Annual European Cancer Congress; 2013 Sept 27-Oct 1; Amsterdam, the Netherlands: ESMO; 2013. Abstract nr 10.
18. Banerjee S, Kaye SB. New strategies in the treatment of ovarian cancer: current clinical perspectives and future potential. Clin Cancer Res 2013;19:961-8.
19. Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 2012;366:1382-92.
20. Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol 2014;15:852-61.
21. Herzog TJ, Armstrong DK, Brady MF, Coleman RL, Einstein MH, Monk BJ, et al. Ovarian cancer clinical trial endpoints: Society of Gynecologic Oncology white paper. Gynecol Oncol 2014;132:8-17.
22. Matulonis UA, Oza AM, Ho TW, Ledermann JA. Intermediate clinical endpoints: a bridge between progression-free survival and overall survival in ovarian cancer trials. In press.
23. Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V, et al. JAK inhibition with ruxolitinib versus best available therapy for myelo fibrosis. N Engl J Med 2012;366:787-98
24. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, et al. TARGET Study Group. Sorafenib in advanced clear-cell renal cell carcinoma. N Engl J Med 2007;356:125-34.
25. Galic V, Coleman RL, Herzog TJ. Unmet needs in ovarian cancer: dividing histologic subtypes to exploit novel targets and pathways. Curr Cancer Drug Targets 2013;13:698-707.
26. Vaughan S, Coward JI, Bast RC, Berchuck A, Berek JS, Brenton JD, et al. Rethinking ovarian cancer: recommendations for improving outcomes. Nature Rev 2011;11:719-25.
27. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011;474:609-15.
28. Berns EM, Bowtell DD. The changing view of high-grade serous ovarian cancer. Cancer Res 2012;72:2701-4.
29. Tothill RW, Tinker AV, George J, Brown R, Fox SB, Lade S, et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res 2008;14:5198-208.
30. Bentink S, Haibe-Kains B, Risch T, Fan JB, Hirsch MS, Holton K, et al. Angiogenic mRNA and microRNA gene expression signature predicts a novel subtype of serous ovarian cancer. PLoS ONE 2012;7:e30269.
31. Alsop K, Fereday S, Meldrum C, deFazio A, Emmanuel C, George J, et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol 2012;30:2654-63.
32. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: genetic/familial high-risk assessment: breast and ovarian [Internet]. Fort Washington, PA: The Network; 2010 [cited 2014 Jul 10]. Available from: http://www.nccn.org.
33. Verhaak RG, Tamayo P, Yang JY, Hubbard D, Zhang H, Creighton CJ, et al. Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. J Clin Invest 2013;123:517-25.
34. Gourley C, McCavigan A, Perren T, Paul J, Ogilvie Michie C, Churchmanet M, et al. Molecular subgroup of high grade ovarian cancer (HGSOC) as a predictor of outcome following bevacizumab. J Clin Oncol 32:5s, 2014 (suppl; abstr 5502).
35. Winterhoff BJN, Kommoss S, Oberg AL, Wang C, Riska SM, Konecny GE, et al. Bevacizumab may differentially improve survival for patients with the proliferative and mesenchymal molecular subtype of ovarian cancer. J Clin Oncol 32:5s, 2014 (suppl; abstr 5509).
36. Bashashati A, Ha G, Tone A, Ding J, Prentice LM, Roth A, et al. Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling. J Pathol 2013;231:21-34.
37. Brown J, Frumovitz M. Mucinous tumors of the ovary: current thoughts on diagnosis and management. Curr Oncol Rep 2014;16:389.
38. Despierre E, Yesilyurt BT, Lambrechts S, Johnson N, Verheijen R, van der Burg M, et al. Epithelial ovarian cancer: rationale for changing the one-fits-all standard treatment regimen to subtype-specific treatment. Int J Gynecol Cancer 2014;24:468-77.
39. Tan DS, Iravani M, McCluggage WG, Lambros MB, Milanezi F, Mackay A, et al. Genomic analysis reveals the molecular heterogeneity of ovarian clear cell carcinomas. Clin Cancer Res 2011;17:1521-34.
40. Farley J, Brady WE, Vathipadiekal V, Lankes HA, Coleman R, Morgan MA, et al. Selumetanib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study. Lancet Oncol 2013;14:134-40.
41. Pennington KP, Walsh T, Harrell MI, Lee MK, Rendi MH, Thornton A, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res 2014;20:764-75.
42. du Bois A, Kristensen G, Ray-Coquard I, Reub A, Pignata P, Columbo N , et al. AGO-OVAR12: a randomized placebo-controlled GCIG/ENGOT intergroup phase III trial of standard frontline chemotherapy +/- nintedanib for advanced ovarian cancer. Int J Gynecol Cancer 2013;23(8 Suppl 1):S7-8.
43. Matulonis UA, Berlin S, Ivy P, Tyburski K, Krasner C, Zarwan C, et al. Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. J Clin Oncol 2009;27:5601-6.
44. Liu JF, Konstantinopoulos PA, Matulonis UA. PARP inhibitors in ovarian cancer: current status and future promise. Gynecol Oncol 2014;133:362-9.
45. Audeh MW, Carmichael J, Penson RT, Friedlander M, Powell B, Bell-McGuinn KM, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 2010;376:245-\51.
46. Gelmon KA, Tischkowitz M, Mackay H, Swenerton K, Robidoux A, Tonkin K, et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol 2011;12:852-61.
47. Advisory Committees. June 25, 2014: Oncologic Drugs Advisory Committee Meeting. 2014 [cited 2014 Jul 10]. Available from: http://www.fda.gov/AdvisoryCommittees/Calendar/ucm394126.htm.
48. Kristeleit R, Burris H, LoRusso P, Patel M, Giordano H, Evans J, et al. Phase I study of continuous oral rucaparib: analysis of patient subgroup with ovarian/peritoneal cancer. Int J Gynecol Cancer 2013;23(8 Suppl 1):S564.
49. Sandhu SK, Schelman WR, Wilding G, Moreno V, Baird RD, Miranda S, et al. The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. Lancet Oncol 2013;14:882-92.
50. Coleman R, Sill M, Aghajanian C, Gray HJ, Tewari KS, Rubin SC, et al. A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1orBRCA2 mutation - a Gynecologic Oncology Group study. Gynecol Oncol 2014;133(8 Suppl 1):S262-63.
51. Lee JM, Hays JL, Annunziata CM, Noonan AM, Minasian L, Zujewski JA, et al. Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses. J Natl Cancer Inst 2014;106:dju089.
52. Oza AM, Cibula D, Oaknin A, Poole CJ, Mathijssen RHJ, Sonke GS, et al. Olaparib plus paclitaxel plus carboplatin (P/C) followed by olaparib maintenance treatment in patients with platinum-sensitive recurrent serous ovarian cancer: a randomized, open-label phase II study. J Clin Oncol 30:15s, 2012 (suppl; abstr 5001).
53. Liu JF, Barry WT, Birrer M, Lee JM, Buckanovich RJ, Fleming GF, et al. Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study. Lancet Oncol 2014 Sep 10. [Epub ahead of print].
54. Juvekar A, Burga LN, Hu H, Lunsford EP, Ibrahim YH, Balmana J, et al. Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer. Cancer Discov 2012 2:1048-63.
55. Ibrahim YH, García-García C, Serra V, He L, Torres-Lockhart K, Prat A, et al. PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition. Cancer Discov 2012 2:1036-47.
56. Matulonis U, Wulf GM, Birrer MJ, Westin SN, Quy P, Bell-McGuinn KM, et al. Phase I of oral BKM120 and oral olaparib for high grade serous ovarian cancer or triple negative breast cancer. J Clin Oncol 32:5s, 2014 (suppl; abstr 2510).
57. Johnson N, Li YC, Walton ZE, Cheng KA, Li D, Rodig S, et al. Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition. Nat Med 2011;17:875-82.
58. Choi YE, Battelli C, Watson J, Liu J, Curtis J, Morse AN, et al. Sublethal concentrations of 17-AAG suppress homologous recombination DNA repair and enhance sensitivity to carboplatin and olaparib in HR proficient ovarian cancer cells. Oncotarget 2014;5:2678-87.
59. Hong DS, Garrido-Laguna I, Ekmekcioglu S, Falchook GS, Naing A, Wheler JJ, et al. Dual inhibition of the vascular endothelial growth factor pathway: a phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors. Cancer 2014;120:2164-73.
60. Azad NS, Posadas EM, Kwitkowski VE, Steinberg SM, Jain L, Annunziata CM, et al. Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J Clin Oncol 2008;26:3709-14.
61. Glickman MS, Sawyers CL. Converting cancer therapies into cures; lessons from infectious diseases. Cell 2012;148:1089-98.
62. Sheppard KE, Cullinane C, Hannan KM, Wall M, Chan J, Barber F, et al. Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors. Eur J Cancer 2013;49:3936-44.
63. Weroha SJ, Becker MA, Enderica-Gonzalez S, Harrington SC, Oberg AL, Maurer MJ, et al. Tumorgrafts as in vivo surrogates for women with ovarian cancer. Clin Cancer Res 2014;20:1288-97.
64. Konstantinopoulos PA, Matulonis UA. Current status and evolution of preclinical drug development models of epithelial ovarian cancer. Front Oncol 2013;3:296.
65. Hodi FS, Butler M, Oble DA, Seiden MV, Haluska FG, Kruse A, et al. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acac Sci U S A 2008;105:3005-10.
66. Hamanishi J, Mandai M, Ikeda T, Minami M, Kawaguchi A, Matsumura N, et al. Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS-936558, ONO-4538) in patients with platinum-resistant ovarian cancer. J Clin Oncol 32:5s, 2014 (suppl; abstr 5511).
67. Etemadmoghadam D, Weir BA, Au-Yeung G, Alsop K, Mitchell G, George J, et al. Synthetic lethality between CCNE1 amplification and loss of BRCA1. Proc Natl Acad Sci U S A 2013;110:19489-94.
68. Calia M. Merck, Endocyte halt study of ovarian cancer treatment [Internet]. The Wall Street Journal. 2014 May 2 [cited 2014 Jul 10]. Available from: http://online.wsj.com/news/articles/SB10001424052702303678404579537500085083982.
69. Eisai/Morphotek's farletuzumab fails on ovarian cancer Ph III trial [Internet]. The Pharma Letter. 2013 Jan 14 [cited 2014 Jul 10]. Available from: http://www.thepharmaletter.com/article/eisai-morphotek-s-far-letuzumab-fails-on-ovarian-cancer-ph-iii-trial.
70. Musrap N, Diamandis EP. Revisiting the complexity of the ovarian cancer microenvironment-clinical implications for treatment strategies. Mol Cancer Res 2012;10:1254-64.
71. Davidson B, Trope CG, Reich R. The role of the tumor stroma in ovarian cancer. Front Oncol 2014;4:104.
72. Fotopoulou C, Vergote I, Mainwaring P, Bidzinski M, Vermorken JB, Ghamande SA, et al. Weekly AUC2 carboplatin in acquired platinumresistant ovarian cancer with or without oral phenoxodiol, a sensitizer of platinum cytotoxicity: the phase III OVATURE multicenter randomized study. Ann Oncol 2014;25:160-5.
73. Glasspool RM, Brown R, Gore ME, Rustin GJ, McNeish IA, Wilson RH, et al. A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in combinationwith carboplatin vs carboplatin alone in patientswith recurrent, partially platinum-sensitive ovarian cancer. Br J Cancer 2014;110:1923-9.
74. Kang Y, Hu W, Ivan C, Dalton HJ, Miyake T, Pecot CV, et al. Role of focal adhesion kinase in regulating YB-1-mediated paclitaxel resistance in ovarian cancer. J Natl Cancer Inst 2013;105:1485-95.
75. Stone RL, Baggerly KA, Armaiz-Pena GN, Kang Y, Sanguino AM, Thanapprapasr D, et al. Focal adhesion kinase: an alternative focus for anti-angiogenesis therapy in ovarian cancer. Cancer Biol Ther 2014;15:919-29.